Randomized Study of Silq Urinary Catheter

UTI Clinical Trial

Official title:

Prospective, Multi-Center, Randomized Study to Assess the Ability of the Silq ClearTract™ Urinary Catheter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-coated Latex)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04841226
• Other study ID #: STC-001/F
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 28, 2021
• Est. completion date: March 31, 2024

Study information

• Verified date: January 2024
• Source: Silq Technologies Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce biofilm formation in subjects that require a long-term indwelling Foley catheter when compared to other commercially available urinary catheters.

Description:

A prospective, randomized, multi-center, post-market study in subjects that require a long-term indwelling Foley catheter.

A randomly assigned catheter will be inserted using standard techniques. Non-surgical subjects will rate the level of pain associated with the insertion procedure using the visual analog scale (VAS). A urine sample will be collected immediately after catheter insertion, in order to generate a baseline urinalysis and urine culture.

Follow-up visits will be performed on Day 28, or upon catheter removal, whichever occurs first. The catheter will be removed on Day 28 or earlier if clinically indicated. The removed catheter will be processed and sent to the core laboratory for analysis. Urine will be collected immediately prior to catheter removal in order to conduct urinalysis and urine culture. Subject will rate level of pain associated with the removal procedure using the VAS. The subject will also fill out a questionnaire about their experience with the catheterization immediately after catheter removal. Subjects will then be exited from the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 158
• Est. completion date: March 31, 2024
• Est. primary completion date: February 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female age = 18 years old;

2. Requiring indwelling 16Fr Foley catheter for at least 7 days;

3. Able and willing to comply with study procedure; and,

4. Able and willing to give informed consent.

Exclusion Criteria:

1. Allergy or sensitivity to any catheter materials used in this study;

2. Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheter;

3. Planned Prophylactic use of antibiotics for CAUTI or any other infection beyond day 1 of the study (catheter implantation);

4. Symptomatic UTI being treated with antibiotics (as determined by the study PI, including at least one of the following: fever, chills, headache, burning sensation, burning of urethra or genital area, blood in urine, foul smelling urine and = 10,000 cfu/mL);

5. Any other infection being treated with antibiotics at the time of catheter implantation;

6. Subjects requiring bladder irrigation during the study (an active voiding trial in surgical subjects prior to catheter removal is allowed);

7. Currently enrolled in another interventional clinical trial;

8. Any other condition that, in the opinion of the investigator, precludes study participation or poses a significant hazard in case of study participation; and

9. Females who are pregnant or breastfeeding or who plan to become pregnant during the study.

Related Conditions & MeSH terms

• Biofilm Formation
• UTI

Intervention

Device:
• Long-term indwelling Foley catheter
Foley Catheter inserted for up to 28-days

Locations

Country	Name	City	State
United States	Montefiore Medical Center	Bronx	New York
United States	Rancho Los Amigos National Rehabilitation Center	Downey	California
United States	Evergreen Health	Kirkland	Washington
United States	West Los Angeles VA Medical Center	Los Angeles	California
United States	Tri Valley Urology Medical Group	Murrieta	California
United States	Providence Saint John's Health Center	Santa Monica	California
United States	Urology Associates of Southern Arizona	Tucson	Arizona
United States	The Iowa Clinic	West Des Moines	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Silq Technologies Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biofilm formation	A core lab will use the BacTiter-Glo Microbial Cell Viability Assay, a well characterized method for quantifying active biomass and biofilm, to determine biofilm formation on explanted catheter samples.	5 to 7 days